About: Telbivudine preserves T‐helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Telbivudine preserves T‐helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Telbivudine preserves T‐helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis
Creator	Wang, X Chen, T Ning, Q Lu, Y Luo, X Wang, H Wu, Z Yan, W Yang, X Zou, Y Guo, W
Source	Medline; PMC
abstract	Summary. Telbivudine is an orally bioavailable L‐nucleoside with potent and specific anti‐hepatitis B virus activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion during telbivudine treatment than other potent anti‐HBV agents suggests a potential immunomodulatory effect. We sought to determine the effects of telbivudine on the immune system, particularly on cytokine production and T‐cell response, using an animal model with mouse hepatitis virus strain 3 (MHV‐3)‐induced hepatitis. The effects of telbivudine on virus replication and cytokine production were investigated in vitro using MHV‐3‐infected macrophages, and the effects on T‐cell response were investigated in vivo in an MHV‐3‐induced viral hepatitis model. Telbivudine had no effect on MHV‐3 replication in macrophages. However, the production of tumour necrosis factor‐α and interleukin‐12 was increased significantly in MHV‐3‐induced macrophages treated with telbivudine. In vivo survival was enhanced in telbivudine‐treated mice, with marked normalization in clinical conditions and histological lesions. Serum levels of interferon‐γ were elevated significantly after telbivudine treatment in MHV‐3‐infected C3H mice. In contrast, serum interleukin‐4 levels were decreased significantly. Furthermore, telbivudine treatment enhanced the ability of T cells to undergo proliferation and secrete cytokines but did not affect cytotoxicity of infected hepatocytes. Of note, we found that telbivudine treatment suppressed programmed death ligand 1 expression on T cells. The results demonstrate the immunomodulatory properties of telbivudine, independent of its antiviral activity, in a mouse model of MHV‐3‐induced hepatitis.
has issue date	2010-03-03(xsd:dateTime)
bibo:doi	10.1111/j.1365-2893.2010.01268.x
bibo:pmid	20586931
has license	no-cc
sha1sum (hex)	2d512e9b7de4d9fa8e65cb4d5ea35f2ba55b8bf2
schema:url	https://doi.org/10.1111/j.1365-2893.2010.01268.x
resource representing a document's title	Telbivudine preserves T‐helper 1 cytokine production and downregulates programmed death ligand 1 in a mouse model of viral hepatitis
has PubMed Central identifier	PMC7166602
has PubMed identifier	20586931
schema:publication	J Viral Hepat
resource representing a document's body	covid:2d512e9b7de4d9fa8e65cb4d5ea35f2ba55b8bf2#body_text
is schema:about of	named entity 'telbivudine' named entity 'T-cell' named entity 'telbivudine' named entity 'hepatitis' named entity 'immunomodulatory' named entity 'nucleoside' named entity 'immunomodulatory' named entity 'interferon' named entity 'programmed death ligand 1' named entity 'immunomodulatory' named entity 'virus infection' named entity 'LPS' named entity 'cytokine' named entity 'immune response' named entity 'TNFR' named entity 'telbivudine' named entity 'telbivudine' named entity 'phorbol myristate acetate' named entity 'treatment of patients' named entity 'viral hepatitis' named entity 'TNF-a' named entity 'staining' named entity 'macrophages' named entity 'Cytolytic activity' named entity 'receptor' named entity 'tumour necrosis factor' named entity 'digestion' named entity 'PD-L1' named entity 'IFN' named entity 'mice' named entity 'telbivudine' named entity 'lamivudine' named entity 'spleen' named entity 'Telbivudine' named entity 'Animal model' named entity 'molecular mechanism' named entity 'upregulation' named entity 'nucleotide analogues' named entity 'Spleens' named entity 'PD-1' named entity 'mice' named entity 'haematopoietic' named entity 'Basel' named entity 'lamivudine' named entity 'phosphorylation' named entity 'liver' named entity 'spleens' named entity 'TNF-a' named entity 'antiviral effect' named entity 'dsRNA' named entity 'seroconversion' named entity 'San Diego' named entity 'ligand' named entity 'hepatocytes' named entity 'Telbivudine' named entity 'thymidine' named entity 'mice' named entity 'viral hepatitis' named entity 'toxic effects' named entity 'dose-dependent manner' named entity 'T-cell' named entity 'T-cell' named entity 'mice' named entity 'telbivudine' named entity 'CD8 +' named entity 'hepatocytes' named entity 'mice' named entity 'mice' named entity 'chronic hepatitis B' named entity 'cytokine' named entity 'murine models'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software